Claims

[Claim 1] An anti-human TSLP receptor antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3.

[Claim 2] The anti-human TSLP receptor antibody according to claim 1, comprising the heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and the light chain consisting of the amino acid sequence shown by SEQ ID NO: 3.

[Claim 3] The anti-human TSLP receptor antibody according to claim 1, comprising the heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 447 of SEQ ID NO: 1, and the light chain consisting of the amino acid sequence shown by SEQ ID NO. 3.

[Claim 4] An expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the antibody according to claim 1 and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody according to claim 1.

[Claim 5] A host cell transformed with an expression vector, which is selected from the group consisting of the following (a) to (b):

(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human TSLP receptor antibody according to claim 1 and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody; and

(b) a host cell transformed with an expression vector comprising a polynucleotide comprising the base sequence encoding the heavy chain variable region of the anti-human TSLP receptor antibody according to claim 1 and an expression vector comprising a polynucleotide comprising the base sequence encoding the light chain variable region of the antibody.

[Claim 6] A host cell transformed with an expression vector, which is selected from the group consisting of the following (a) to (b):

(a) a host cell transformed with an expression vector comprising a polynucleotide comprising the base sequence encoding the heavy chain of the anti-human TSLP receptor antibody according to claim 2 and a polynucleotide comprising the base sequence encoding the light chain of the antibody; and

(b) a host cell transformed with an expression vector comprising a polynucleotide comprising the base sequence encoding the heavy chain of the anti-human TSLP receptor

antibody according to claim 2 and an expression vector comprising a polynucleotide comprising the base sequence encoding the light chain of the antibody.

[Claim 7] A method of producing an anti-human TSLP receptor antibody or an antigen-binding fragment thereof, which comprises culturing the host cell according to claim 5 to express an anti-human TSLP receptor antibody or an antigen-binding fragment thereof.

[Claim 8] A method of producing an anti-human TSLP receptor antibody, which comprises culturing the host cell according to claim 6 to express an anti-human TSLP receptor antibody.

[Claim 9] A pharmaceutical composition comprising the anti-human TSLP receptor antibody or the antigen-binding fragment thereof according to any one of claims 1 to 3 and a pharmaceutically acceptable excipient.

[Claim 10] The pharmaceutical composition according to claim 9, which is the pharmaceutical composition for preventing or treating asthma.

[Claim 11] The anti-human TSLP receptor antibody or the antigen-binding fragment thereof according to any one of claims 1 to 3 for use in preventing or treating asthma.

[Claim 12] Use of the anti-human TSLP receptor antibody or the antigen-binding fragment thereof according to any one of claims 1 to 3 for manufacture of a pharmaceutical composition for preventing or treating asthma.